Article
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
JCO precision oncology - 1 Nov 2021
Eder Joseph P, Doroshow Deborah B, Do Khanh T, Keedy Vicki L, Sklar Jeffrey S, Glazer Peter, Bindra Ranjit, Shapiro Geoffrey I
Abstract excerpt
PURPOSE: Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label study in which patients with solid tumors harboring IDH1/2 mutations were treated with olaparib as monotherapy, with objective response and clinical benefit rates as the primary end...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.